Phase III trial of a 13-valent pneumococcal conjugate vaccine in infants aged 2 or 3 months

Phase 3 trial of pneumococcal 13-valent conjugate vaccine in pneumococcal disease (3 arms), sponsored by Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention. Primary endpoints: Seroprotection rate of 13 vaccine serotype-specific pneumococcal IgG antibodies after primary immunization, Geometric mean concentration of 13 vaccine serotype-specific pneumococcal IgG antibodies after primary immunization and 3 more. Started Nov 2022; status: recruiting.